Royal Bank of Canada’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-6,372
| Closed | -$118K | – | 7863 |
|
|
2023
Q3 | $118K | Buy |
6,372
+3,407
| +115% | +$38.5K | ﹤0.01% | 5273 |
|
|
2023
Q2 | $33K | Sell |
2,965
-5,413
| -65% | -$75.4K | ﹤0.01% | 5969 |
|
|
2023
Q1 | $112K | Sell |
8,378
-4,649
| -36% | -$80.4K | ﹤0.01% | 5096 |
|
|
2022
Q4 | $161K | Buy |
13,027
+2,490
| +24% | +$35.3K | ﹤0.01% | 5070 |
|
|
2022
Q3 | $147K | Buy |
10,537
+164
| +2% | +$2.64K | ﹤0.01% | 5024 |
|
|
2022
Q2 | $144K | Sell |
10,373
-1,395
| -12% | -$22.3K | ﹤0.01% | 5065 |
|
|
2022
Q1 | $191K | Sell |
11,768
-5,545
| -32% | -$86.9K | ﹤0.01% | 5134 |
|
|
2021
Q4 | $281K | Buy |
17,313
+3,429
| +25% | +$57.8K | ﹤0.01% | 5004 |
|
|
2021
Q3 | $206K | Sell |
13,884
-66,308
| -83% | -$1.06M | ﹤0.01% | 5144 |
|
|
2021
Q2 | $1.6M | Buy |
80,192
+3,090
| +4% | +$61.3K | ﹤0.01% | 3247 |
|
|
2021
Q1 | $1.78M | Buy |
77,102
+890
| +1% | +$24.8K | ﹤0.01% | 3106 |
|
|
2020
Q4 | $1.88M | Sell |
76,212
-2,326
| -3% | -$77.1K | ﹤0.01% | 2971 |
|
|
2020
Q3 | $3.26M | Sell |
78,538
-31,029
| -28% | -$1.43M | ﹤0.01% | 2308 |
|
|
2020
Q2 | $5.25M | Sell |
109,567
-10,221
| -9% | -$790K | ﹤0.01% | 1914 |
|
|
2020
Q1 | $7.54M | Sell |
119,788
-11,534
| -9% | -$1.04M | ﹤0.01% | 1536 |
|
|
2019
Q4 | $16.3M | Sell |
131,322
-4,404
| -3% | -$394K | 0.01% | 1293 |
|
|
2019
Q3 | $9.01M | Buy |
135,726
+11,295
| +9% | +$758K | ﹤0.01% | 1643 |
|
|
2019
Q2 | $9.9M | Buy |
124,431
+6,778
| +6% | +$607K | ﹤0.01% | 1571 |
|
|
2019
Q1 | $13.2M | Buy |
117,653
+23,731
| +25% | +$2.59M | 0.01% | 1327 |
|
|
2018
Q4 | $9.47M | Buy |
93,922
+3,307
| +4% | +$343K | ﹤0.01% | 1520 |
|
|
2018
Q3 | $11.4M | Sell |
90,615
-24,496
| -21% | -$2.59M | ﹤0.01% | 1528 |
|
|
2018
Q2 | $9.66M | Buy |
115,111
+22,644
| +24% | +$1.66M | ﹤0.01% | 1559 |
|
|
2018
Q1 | $5.69M | Sell |
92,467
-2,459
| -3% | -$148K | ﹤0.01% | 1904 |
|
|
2017
Q4 | $5.55M | Buy |
94,926
+4,416
| +5% | +$278K | ﹤0.01% | 1990 |
|
|
2017
Q3 | $5.25M | Buy |
90,510
+6,911
| +8% | +$744K | ﹤0.01% | 1950 |
|
|
2017
Q2 | $10.1M | Sell |
83,599
-248
| -0.3% | -$28.7K | 0.01% | 1499 |
|
|
2017
Q1 | $9.48M | Sell |
83,847
-135
| -0.2% | -$15.8K | 0.01% | 1518 |
|
|
2016
Q4 | $9.13M | Buy |
83,982
+9,884
| +13% | +$1.18M | ﹤0.01% | 1571 |
|
|
2016
Q3 | $12.2M | Buy |
74,098
+67,911
| +1,098% | +$10.7M | 0.01% | 1353 |
|
|
2016
Q2 | $883K | Sell |
6,187
-636
| -9% | -$92.7K | ﹤0.01% | 3219 |
|
|
2016
Q1 | $875K | Sell |
6,823
-48,406
| -88% | -$5.72M | ﹤0.01% | 3176 |
|
|
2015
Q4 | $8.25M | Buy |
55,229
+42,553
| +336% | +$7.2M | 0.01% | 1555 |
|
|
2015
Q3 | $2.1M | Sell |
12,676
-2,567
| -17% | -$565K | ﹤0.01% | 2234 |
|
|
2015
Q2 | $3.68M | Sell |
15,243
-518
| -3% | -$138K | ﹤0.01% | 1821 |
|
|
2015
Q1 | $4.44M | Buy |
15,761
+3,367
| +27% | +$729K | ﹤0.01% | 1682 |
|
|
2014
Q4 | $1.93M | Buy |
12,394
+1,577
| +15% | +$291K | ﹤0.01% | 2364 |
|
|
2014
Q3 | $2.56M | Buy |
10,817
+4,101
| +61% | +$1.05M | ﹤0.01% | 2112 |
|
|
2014
Q2 | $1.59M | Buy |
6,716
+6,166
| +1,121% | +$1.63M | ﹤0.01% | 2471 |
|
|
2014
Q1 | $181K | Buy |
+550
| New | +$186K | ﹤0.01% | 4183 |
|
|
2013
Q4 | – | Sell |
-80
| Closed | -$6K | – | 6208 |
|
|
2013
Q3 | $6K | Buy |
+80
| New | +$3.95K | ﹤0.01% | 5594 |
|
Royal Bank of Canada's ICPT Position: Q4 2023 in Review
Royal Bank of Canada sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 6,372 shares — an estimated $118K sold.
Royal Bank of Canada first reported a position in ICPT in Q3 2013 and held it in 40 quarters. The position peaked at $16.3M in Q4 2019. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Royal Bank of Canada reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Royal Bank of Canada sold 6,372 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $118K.
- Royal Bank of Canada first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2013 and held it in 40 quarters.
- Royal Bank of Canada's Intercept Pharmaceuticals, Inc. position peaked at $16.3M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Royal Bank of Canada's 13F filing for Q4 2023, filed 14 Feb 2024.